Corbus Pharmaceuticals Holdings Inc
CRBP
Get informed when a big investor buys or sells
+ FollowMarket Cap$113.58M
Close$
$2.02
67.1% downside
Current Fair Value
67.1% downsideOvervalued by 67.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $113.58 Million |
|---|---|
| Enterprise Value | $94.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.9 |
| Beta | 2.64 |
| Outstanding Shares | 19,407,688 |
Return
| Return on Equity | -99.67% |
|---|---|
| Return on Assets | -80.25% |
| Return on Invested Capital | -22.91% |
Valuation & Multiples
| P/E Ratio | -0.95 |
|---|---|
| PEG | -0.96 |
| Price to Sales | - |
| Price to Book Ratio | 1.23 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.91 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-1.26
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-1.21
Average shareholder expectationRevenue Estimate
$2.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Corbus Pharmaceuticals Holdings, Inc.
28 employees
CEO: Dr. Yuval Cohen Ph.D. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid...